Teva (NYSE: TEVA) EVP sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP U.S. Commercial Christine Fox reported RSU vesting, a new RSU grant, and a related share sale. On March 4, 2026 she acquired 20,461 ordinary shares through the exercise of restricted share units and received a grant of 50,643 restricted share units. She then sold 9,098 ordinary shares at a weighted average price of $32.4645 pursuant to a Rule 10b5-1 trading plan, with the sale representing shares required to cover tax withholding from the RSU vesting, leaving her with 75,010 ordinary shares held directly.

Insider Trade Summary

Net Seller: 9,098 shares ($295,362)

Net Sell 4 txns

Insider Fox Christine

Role EVP, U.S. Commercial

Sold 9,098 shs ($295K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	20,461	$0.00	--
Grant/Award	Restricted Share Units	50,643	$0.00	--
Exercise	Ordinary Shares	20,461	$0.00	--
Sale	Ordinary Shares	9,098	$32.4645	$295K

Holdings After Transaction: Restricted Share Units — 40,923 shares (Direct); Ordinary Shares — 84,108 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Christine

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, U.S. Commercial

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/04/2026		M		20,461	A	(2)	84,108	D
Ordinary Shares(1)	03/04/2026		S(3)		9,098(4)	D	$32.4645(5)	75,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/04/2026		M			20,461	(6)	(6)	Ordinary Shares(1)	20,461	$0	40,923	D
Restricted Share Units	(2)	03/04/2026		A		50,643		(7)	(7)	Ordinary Shares(1)	50,643	$0	50,643	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028.

7. Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030.

	/s/ Dov Bergwerk as attorney-in-fact for Christine Fox	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TEVA executive Christine Fox report in this Form 4 filing?

Christine Fox, EVP U.S. Commercial at Teva, reported RSU vesting, a new restricted share unit grant, and a related share sale. The filing details derivative exercises, an award of 50,643 RSUs, and an open-market sale of 9,098 ordinary shares tied to tax withholding.

How many Teva shares did Christine Fox sell on March 4, 2026?

On March 4, 2026, Christine Fox sold 9,098 ordinary shares of Teva. Footnotes state this represented shares required to cover tax withholding obligations from RSU vesting, executed under a Rule 10b5-1 trading plan at a weighted average price of $32.4645 per share.

What restricted share unit activity did TEVA report for Christine Fox?

Christine Fox exercised 20,461 restricted share units, receiving an equal number of ordinary shares at no exercise price, and was granted 50,643 new restricted share units. Footnotes outline vesting schedules through March 4, 2030, with future tranches vesting annually in specified amounts.

How many Teva ordinary shares does Christine Fox hold after these transactions?

After the reported transactions, Christine Fox directly holds 75,010 ordinary shares of Teva. This balance reflects RSU conversion into 20,461 shares and the sale of 9,098 shares to satisfy tax withholding related to vesting on March 4, 2026.

Were Christine Fox’s Teva share sales under a trading plan?

Yes. The filing notes the March 4, 2026 transaction was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025. Such plans pre-schedule trades, providing structure and helping separate personal trading decisions from later nonpublic information.

How are Teva restricted share units settled for Christine Fox?

Each restricted share unit for Christine Fox represents a right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. Footnotes clarify this structure for the RSU awards reported.